William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN)

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at William Blair in a note issued to investors on Wednesday,RTT News reports. William Blair also issued estimates for VistaGen Therapeutics' Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.48) EPS and Q4 2027 earnings at ($0.41) EPS.

VistaGen Therapeutics Stock Down 2.9%

NASDAQ:VTGN traded down $0.06 during trading hours on Wednesday, reaching $2.00. 389,042 shares of the stock were exchanged, compared to its average volume of 174,249. The company has a market capitalization of $58.32 million, a price-to-earnings ratio of -1.20 and a beta of 0.70. VistaGen Therapeutics has a twelve month low of $1.90 and a twelve month high of $4.21. The business has a 50-day moving average of $2.31 and a two-hundred day moving average of $2.57.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last released its earnings results on Tuesday, June 17th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.10. The company had revenue of ($0.01) million for the quarter, compared to analyst estimates of $0.18 million. VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 58.88%. During the same period in the prior year, the business earned ($0.25) EPS. On average, research analysts forecast that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VTGN. Blair William & Co. IL boosted its holdings in VistaGen Therapeutics by 11.3% in the fourth quarter. Blair William & Co. IL now owns 98,466 shares of the company's stock valued at $290,000 after purchasing an additional 10,000 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics during the first quarter worth about $25,000. Two Sigma Advisers LP purchased a new position in shares of VistaGen Therapeutics during the 4th quarter worth approximately $35,000. Millennium Management LLC raised its position in VistaGen Therapeutics by 52.9% in the fourth quarter. Millennium Management LLC now owns 38,732 shares of the company's stock worth $114,000 after acquiring an additional 13,395 shares in the last quarter. Finally, Man Group plc purchased a new stake in VistaGen Therapeutics during the fourth quarter worth about $54,000. Hedge funds and other institutional investors own 78.39% of the company's stock.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.